Darbepoetin alfa biosimilar (PanPharmaceuticals)

阿法达贝泊汀生物类似药 (PanPharmaceuticals)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDarbepoetin alfa biosimilar (PanPharmaceuticals)

Drug Alias Name达依泊汀α生物仿制药 (PanPharmaceuticals)阿法达贝泊汀生物仿制药 (PanPharmaceuticals)阿法达贝汀生物仿制药 (PanPharmaceuticals)达贝泊汀α生物仿制药 (PanPharmaceuticals)达促红素α生物仿制药 (PanPharmaceuticals)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Biosimilar

Mechanisms of ActionErythropoietin receptor agonists

TargetsErythropoietin receptor

Therapy Area/IndicationsAnemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesPanpharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesPanpharmaceuticals

Inactive CompaniesN/A

Active IndicationsAnemia

Inactive IndicationsN/A

Other Information

ATC CodeB03XA02